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Abstract
Objective: In 2013 we started to combine VATS poudrage with simultaneous insertion of an indwelling pleural
catheter (IPC) for management of malignant pleural effusions (MPE) to achieve successful pleurodesis, avoid
recurrence of MPE and shorten hospitalization time. The aim of this study was to distinguish whether the
combination treatment is superior over standard VATS poudrage.
Methods: This retrospective descriptive study analyses data of patients with MPE treated at our department
since the implementation of the method. The historic control group included patients with MPE treated with VATS
poudrage alone.
Results: There were 117 patients, 67 patients were treated with the new approach (IPC group) and 50 patients
with VATS talc poudrage (control group). Both groups were comparable in demographic data. The postoperative
hospitalization time was significantly shorter in the IPC group (P=0.0001). Patients in the control group got 2 chest
drains inserted (Ch 24/Ch 28) and in the IPC group 1 chest drain (Ch 24) plus the IPC. Chest drains could be
removed quicker in the IPC group (P=<0.0001). So far there was not a single case of unsuccessful pleurodesis with
our approach compared to 10% failure rate in the control group.
Conclusion: The combined approach is a safe and effective approach in MPE prophylaxis. Patients were
discharged earlier and further treatment, e.g., chemotherapy, could be initiated in time.
Keywords: Malignant pleural effusion; Talc pleurodesis; Indwelling
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Introduction
The main focus of the treatment for MPE is to improve quality of
life, since there is no cure for this condition [1]. The current standard
treatment strategy for malignant pleural effusion (MPE) is talc
pleurodesis, a procedure that has been implemented more than 80
years ago [2]. Today, talc pleurodesis is a safe procedure and talc is
known to be the most successful pleurodesis agent with a success rate
of more than 70% [3-5]. A major disadvantage of the procedure is
however the need of chest tube(s) and the therefore long hospital stay
up to seven days until they can be removed [6].
Indwelling pleural catheters (IPCs) are small-bore silicone tubes,
which can be left in place for weeks or even months. Intermittent fluid
drainage is needed until efficient pleurodesis occurs [6]. The use of
IPCs improves the quality of life in patients [7]. The insertion of an
IPC can reduce the hospitalization time in case of malignant pleural
effusion since they can be inserted as an outpatient procedure [8].
In this retrospective analysis we report our experience with the
VATS talc pleurodesis and the concomitant insertion of IPC in
comparison to VATS talcs pleurodesis only.
This new treatment protocol was intended to induce a better pleural
adhesion, as the IPC would render the pleural space permanently dry
over a longer period than in the normal VATS talcage procedure. Our
hypothesis was that a combination of both therapies offers new
possibilities for efficient pleurodesis and shortens the hospitalization
time.
Materials and Methods
Since February 2013 VATS poudrage with simultaneous insertion of
an IPC has been routinely performed for treatment of malignant
pleural effusion at the Division of General Thoracic Surgery, Bern
University Hospital, Switzerland. All patients undergoing this surgical
procedure were registered in this retrospective trial until the end of
May 2015 (16 months). Surgical techniques and the evaluation of
patients have been uniform with an implemented standard pre-, and
perioperative management from the beginning of the study period in
2013.
The control group consisted of patients, who received VATS talc
poudrage without IPC. With the introduction of the new combination
treatment for malignant pleural effusion only few patients are treated
by VATS poudrage alone. To have a sufficient number of patients in the
control group we thus had to include patients treated at our clinic as
early as January 2012 and until the end of May 2015.
The Ethics Committee of the canton of Bern approved this study
design and informed consent was given (KEK-BE 259/2015)
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Preoperative management
Since February 2013 all patients with a suspected or proven
malignant pleural effusion have been offered a VATS talc pleurodesis
with simultaneous insertion of IPC. Requirements have been a
Karnofsky index >40 and a serum creatinine within the normal range.
In case of curative intention patients with malignant mesothelioma
have been offered VATS poudrage without IPC insertion. Patients with
extreme reduced general condition (Karnofsky <40) received the IPC
in local anesthesia without additional VATS poudrage. Such patients
have been excluded from this trial. We have also excluded patients with
a benign pleural effusion, chylothorax, pneumothorax and empyema
from the analysis.
Perioperative management and surgical techniques
All operations were performed under general anaesthesia, using a
double lumen tube for selective single lung ventilation. VATS talc
poudrage was performed with Steritalc Novatech 4g under video-
thoracoscopic visualization and by specially trained members of our
staff. IPC (PleurX Catheter, CareFusion , USA) and an additionally
chest tube (24 Ch) were inserted. The chest tube was placed to ensure
complete drainage of the pleural fluid and to dry pleural space. The
IPC was tunnelled under the skin for about 5-8 cm and then inserted
in the pleural space through one of the VATS incisions. The cuff mid-
way along the catheter must be placed right behind the entry of the
catheter into the skin. The developing scar tissue around the cuff
established a barrier to prevent infections inside the pleural space. The
thoracic drain and the IPC were set to -20 cm H2O suction as long as
the patient was hospitalized. The standard chest drain was removed
postoperatively and the IPC was left in situ.
The control group consisted of patients, who received VATS talc
(Steritalc Novatech 4 g) poudrage without IPC. All these patients got
two chest tubes (24 Ch and 28 Ch) inserted. According to the
treatment protocol at our institution, the first chest tube was removed
on the 4th postoperative day. The second chest tube was removed
when the fluid secretion was <200 ml/day.
Management in the postoperative course
A routine chest X-ray was performed after the operation in order to
document the position of the IPC and the efficient drainage of the
pleural space. In case of a VATS poudrage without IPC chest X-ray was
done after removal of the second chest tube.
Postoperative follow-up and long-term observation
Patients or their relatives were trained in correct handling of the
IPC for fluid drainage at regular intervals. If they needed support by
home nursing staff, this was organized. All patients with IPC were
routinely seen at the outpatient department two or three weeks
postoperatively. IPC was removed in local anaesthesia in case of daily
fluid amount <50 ml and if there was no residuum of pleural effusion
in the control chest X-ray.
Statistical methods
P-values were calculated using the Mann Whitney U test. Statistical
analysis of the primary and secondary outcomes was performed using
prism statistical software. P-values of less than 0.05 were considered
statistically significant.
Results
Demographics
A total of 117 operative procedures for malignant pleural effusion
were performed at our institution from January 2012 until May 2015.
50 patients received VATS talc poudrage alone and 67 patients got an
insertion of IPC in addition to VATS talc poudrage. A summary of
patient's demographical data and tumour type is shown in Table 1.
IPC group Control group
Number of patients 67 50
Gender
Male: 38 (57%)
Female: 29 (43%)
Male: 36 (72%)
Female: 14 (28%)
Median age M = 67 years (31-86) M = 68 years (49-88)
Primary tumour
(number of patients)
Lung tumour: 21 (28%)
Breast Cancer: 8 (12%)
Mesothelioma: 3 (5%)
Melanoma 3 (5%)
Other: 32 (49%)
Mesothelioma: 17 (34%)
NSCLC: 9 (18%)
Breast Cancer: 5 (10%)
Other: 20 (40%)
Table 1: Patients Characteristics
Both groups are comparable in the underlying tumour type. In the
IPC group there are three patients with MPM, which got also an IPC
inserted because the tumour was widespread and the treatment was
thought to be palliative.
Hospitalization time
In comparison to the control group the overall median length of
stay could be shortened by one day using the combined approach
(seven days vs. eight days). In both groups one patient was hospitalized
for 20 and 43 days, respectively, due to complications in connection
with the underlying malignancy and not related to the thoracic surgery
procedure (Table 2).
IPC group Control group
Overall length of stay (median) 7 days (3-43) 8 days (5-20)
Table 2: Overall length of stay.
Postoperative hospitalization time
The mean postoperative length of stay could be significantly
shortened with our new approach (p<0.0001) (Table 3 and Figure 1).
Time till removal of the standard thoracic drain
Results are listed in Table 4 and Figure 2. In the control group the
chest tubes were removed according to the clinic standard. As a
measure of caution and due to the limited experience with the new
combined approach, we initially removed the chest tube after five days
as well in the IPC group. But with good results we got more confident
and nowadays we remove the standard thoracic drain on the first
postoperative day. The overall median time till removal of the thoracic
drain was significantly shorter as in the control group (p<0.0001).
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There was one patient whose drain was removed on the eighth
postoperative day due to massive subcutaneous emphysema.
Figure 1: Postoperative hospitalisation time.
IPC group Control group
Postoperative hospitalization
time (median)
4.5 days (1-35) 7 days (5-18)
Table 3: Postoperative hospitalization time.
Figure 2: Time till chest drain removal.
IPC group Control group
Days till drain (24 Ch) removal
(median)
3 days (1-8) 5 days (4-16)
Table 4: Time till removal of the thoracic drain.
Complications
We recorded five cases (10%) of unsuccessful pleurodesis with the
thoracoscopic talc pleurodesis alone. There was no case of recurrence
of MPE in the group with the combined approach.
Patient satisfaction
We recorded patient’s satisfaction during the check up at our
outpatient department. 90% of the patients reported to be satisfied
with the course of treatment and intermittent pleural drainage did not
cause them any distress during everyday life.
Discussion
Patients with a malignant pleural effusion should be offered an
effective treatment in terms of effusion prophylaxis. Given their limited
life expectancy, unnecessary hospital admissions must be avoided.
Symptoms like breathlessness and coughing impair their quality of life
[9]. Current therapeutic options are repeated thoracentesis, pleurodesis
or the insertion of an IPC. None of these treatments is perfect and all
have their disadvantages, such as repeated procedures, long
hospitalization or prolonged drainage with a catheter at home [10].
The first line of treatment, for patients in good performance status,
is the insertion of a chest tube followed by pleurodesis [3]. Pleurodesis
can either be performed by application of talc slurry or through VATS.
Both are equally effective. The use of VATS allows a direct inspection
of the pleura, the removing of adhesions and loculations of pleural
fluid and to distribute talc evenly over the pleural surface [5]. VATS
can also be used to obtain pleural biopsies with a diagnostic yield of
91-95% [11]. This makes it more versatile compared to the usage of
simple talc slurries. However, according to control trials there is no
difference in the pleurodesis success rate between the two procedures
[5].
The insertion of an IPC is a safe and effective treatment to avoid
recurrence of pleural effusion [3]. It is also an effective option to
shorten the hospitalization time. It can be inserted on an outpatient
basis as a day care procedure and further care is provided at home by
trained healthcare professionals or by family members. However, there
is a burden of on-going care such as wound dressing changes and
drainages [12]. Nonetheless, according to the TIME2 trial this does not
affect the quality of life in these patients [7]. The probability of
spontaneous pleurodesis with an IPC insertion without additional talc
poudrage lies between 26% and 76% [6,8,13]. The goal of regular
drainage of IPC is symptom relief and promoting spontaneous
pleurodesis by keeping the intrapleural space dry [6]. The IPC was
designed to be left in situ for the remaining lifespan of the patient.
However there is an increasing risk of complications the longer the IPC
is left in place. According to current literature the most common
complications are empyema, unspecified infection, and cellulitis [14].
These complications did not appear to be of major concern in our
study. With the combination of talc and IPC the time till pleurodesis
occurs is shorter and the risk of infection might be lowered because the
IPC is left in situ for a shorter period of time.
The intention to combine both methods-VATS pleurodesis and IPC
insertion–was to get the best out of both. According to our knowledge
this is the first larger scale study combining these different types of
treatment protocols. Furthermore, the combined procedure has not yet
been proven to be beneficial to the patients.
We were not able to show a reduction of the overall hospitalisation
time. Although there was a trend towards shorter hospital stay (seven
days vs. eight days) this is not statistically significant.
A detailed look at the patients showed that the long hospitalization
was caused by complications related to advanced cancer burden in the
preoperative period and not because of the procedure. We did however
show that the postoperative hospitalisation time could be significantly
shortened. Patients with a MPE have many reasons to seek medical
help and unfortunately, MPE is only one of the burdens faced by
patients with advanced cancer disease.
During the period when we were performing thoracoscopic talc
pleurodesis only, we found a failure rate of about 10%. This is
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consistent with current literature. Even in selected patients without
significant trapped lung, the failure rate of pleurodesis 30 days
postoperatively is around 30%. The longer the patient survives, the
higher is the chance of treatment failure [5]. With our combined
approach we did not have any cases of unsuccessful pleurodesis so far.
The concomitant insertion of IPC also offered a more liberal
selection of patients for VATS talc pleurodesis. Even if the lung is
(partially) trapped, the procedure can be done. A trapped lung is a
contraindication for pleurodesis. However this is not always obvious
before the operation, but with the combination therapy, partial
pleurodesis could be achieved. The rest of the pleural fluid can be
drained through IPC.
The treatment, with the combined therapy, at our department was
finished sooner and additional treatment could be initiated earlier. It is
not contraindicated to receive chemotherapy after IPC insertion, since
it does not confer an increased risk of infections [15].
Patients with mesothelioma have a high incidence of tumour
metastasis along IPC and at the side of the VATS ports. Usually the
combined approach was not implemented in these patients. We believe
that the use of IPC catheter in mesothelioma patients should be limited
to those who have advanced disease and not to those whose initial
treatment is thought to be curative. But with advanced symptomatic
mesothelioma, IPCs are an effective method to palliate dyspnea [16].
The indication for this combination treatment needs to be
considered carefully. Patients with a life span of less than a month
should not be offered this procedure. Placement of an IPC under local
anaesthesia is a safe alternative and also improves the quality of life.
Prior studies comparing talc poudrage vs. insertion of an IPC did not
demonstrate a significant difference in performance score and
improvement of quality of life [7].
Patients were asked to come to our department for a check-up two
to three weeks after the operation. However, some of them failed to
come in because their oncologist performed all further care or their
overall performance status was too bad. The IPC could be removed in
about 2/3 of the time at our outpatient department within 1 or 2
months.
The primary aim of malignant pleural effusion management is
palliation. Due to the study design we however lack objective data on
symptom improvement and quality of life. Overall we received a
positive feedback from patients at check-ups at our outpatient clinic.
This positive feedback was encouraging and confirmed that our
method is well accepted among our patients.
The heterogeneity of patients makes a single approach difficult. We
strongly believe in this approach due to the simplicity of IPC insertion,
low likelihood of complication and because it’s uncomplicated use for
the patients. With the overall positive experience we began to remove
the standard thoracic drain on first postoperative day. We even
consider doing the procedure without the additional chest tube In the
future.
Conclusion
Combining VATS talc poudrage and the insertion of IPC is a safe
and effective strategy in pleural effusion prophylaxis. To assure quality
of life in terminally ill cancer patients is the main focus of their overall
care. With our approach we significantly shortened the postoperative
hospitalisation time, we could remove the standard thoracic drain
sooner and we did not have any relapses so far.
Limitations
Retrospective study with incomplete or lost patient data due to
follow up.
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